Cargando…
Efficacy and safety of systemic, high-dose glucocorticoid therapy for idiopathic sudden sensorineural hearing loss: Study protocol for a three-armed, randomized, triple-blind, multicenter trial (HODOKORT)
BACKGROUND: Systemic glucocorticosteroids (“steroids”) are widely used worldwide as a standard of care for primary therapy of idiopathic sudden sensorineural hearing loss (ISSHL). The German ISSHL guideline recommends high-dose steroids without evidence from randomized controlled trials (RCTs) and r...
Autores principales: | Plontke, Stefan K., Girndt, Matthias, Meisner, Christoph, Böselt, Iris, Ludwig-Kraus, Beatrice, Richter, Michael, Rahne, Torsten |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Medizin
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9208545/ https://www.ncbi.nlm.nih.gov/pubmed/35725822 http://dx.doi.org/10.1007/s00106-022-01184-8 |
Ejemplares similares
-
Intratympanic corticosteroids for sudden sensorineural hearing loss
por: Plontke, Stefan K, et al.
Publicado: (2022) -
Glucocorticoid influence on prognosis of idiopathic sudden sensorineural hearing loss()
por: Bogaz, Eduardo Amaro, et al.
Publicado: (2014) -
Correlations of MIF polymorphism and serum levels of
MIF with glucocorticoid sensitivity of sudden sensorineural hearing
loss
por: Zhu, Wen-Yan, et al.
Publicado: (2019) -
Response of Glucocorticoid Receptor Alpha and Histone Deacetylase 2 to Glucocorticoid Treatment Predicts the Prognosis of Sudden Sensorineural Hearing Loss
por: Zhang, Xiuling, et al.
Publicado: (2019) -
Influence of transducer types on bone conduction hearing thresholds
por: Fröhlich, Laura, et al.
Publicado: (2018)